High Dose Thoracic Re-Irradiation and Chemo-Immunotherapy for Centrally Recurrent NSCLC
Authors:
- Brane GrambozovBGBrane Grambozov
- Markus StanaMSMarkus Stana
- Bernhard KaiserBKBernhard Kaiser
- Josef KarnerJKJosef Karner
- Sabine GerumSGSabine Gerum
- Elvis RuznicERElvis Ruznic
- Barbara ZellingerBZBarbara Zellinger
- Raphaela MoosbruggerRMRaphaela Moosbrugger
- Michael StudnickaMSMichael Studnicka
- Gerd FastnerGFGerd Fastner
- Felix SedlmayerFSFelix Sedlmayer
- Franz ZehentmayrFranz Zehentmayr
Open Access
Abstract
Introduction: Thoracic re-irradiation for recurrent lung cancer dates back four decades, when the first small series on 29 patients receiving palliative doses was published. With 5-year overall survival rates of 57% in PDL-1 positive patients after primary chemo-radio-immunotherapy, the number of patients who experience loco-regional relapse will increase in the near future. In this context, centrally recurring lung tumors pose a major treatment challenge. Hence, the aim of the current review is to compile the available evidence on curatively intended thoracic re-irradiation for this special clinical situation. Methods: A systematic literature search according to the PRISMA guidelines was performed. A study was included when the following criteria were met: (1) 66% of the patients had NSCLC, (2) a total dose of 50 Gy in the second course and/or a biologically effective dose of at least 100 Gy in both treatment courses was administered, (3) re-irradiation was administered with modern radiation techniques, (4) 50% or more of the patients had a centrally located relapse, (5) the minimum cohort size was 30 patients. Results: Of the initial 227 studies, 11 were analyzed, 1 of which was prospective. Median overall survival (OS) was 18.1 months (range 9.3–25.1), median progression free survival (PFS) was nine months (range 4.5–16), and median loco-regional control (LRC) was 12.1 months (range 6.5–20). Treatment-related mortality rates ranged from 2% to 14%. The total dose at re-irradiation correlated with both LRC (p-value = 0.012) and OS (p-value = 0.007) with a close relation between these two clinical endpoints (p-value = 0.006). The occurrence of acute toxicity grade 1 to 4 depended on the PTV size at re-irradiation (p-value = 0.033). Conclusion: The evidence regarding curative re-irradiation for centrally recurrent NSCLC is primarily based on scarce retrospective data, which are characterized by a high degree of heterogeneity. The OS in this clinically challenging situation is expected to be around 1.5 years after re-treatment. Patients with a good performance score, younger age, small tumors, and a longer interval to recurrence potentially benefit most from re-irradiation. In this context, prospective trials are warranted to achieve substantial advances in the field.Keywords
This publication has 49 references indexed in Scilit:
- Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2013
- Reirradiation and stereotactic radiotherapy for tumors in the lung: Dose summation and toxicityRadiotherapy and Oncology, 2013
- The use of fused PET/CT images for patient selection and radical radiotherapy target volume definition in patients with non-small cell lung cancer: Results of a prospective study with mature survival dataRadiotherapy and Oncology, 2013
- Aortic dose constraints when reirradiating thoracic tumorsRadiotherapy and Oncology, 2013
- Re-irradiation plus regional hyperthermia for recurrent non-small cell lung cancer: A potential modality for inducing long-term survival in selected patientsLung Cancer, 2012
- Sequential vs Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer: Randomized Phase III Trial RTOG 9410JNCI: Journal of the National Cancer Institute, 2011
- Second re-irradiation: Efficacy, dose and toxicity in patients who received three courses of radiotherapy with overlapping fieldsRadiotherapy and Oncology, 2011
- B7-H1–Dependent Sex-Related Differences in Tumor Immunity and Immunotherapy ResponsesThe Journal of Immunology, 2010
- Radiation Dose–Volume Effects in the HeartInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2010
- Excessive Toxicity When Treating Central Tumors in a Phase II Study of Stereotactic Body Radiation Therapy for Medically Inoperable Early-Stage Lung CancerJournal of Clinical Oncology, 2006